Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novo Nordisk A/S (NVO)

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 151,196,864
  • Shares Outstanding, K 2,368,001
  • Annual Sales, $ 18,291 M
  • Annual Income, $ 5,839 M
  • 60-Month Beta 0.63
  • Price/Sales 8.22
  • Price/Cash Flow 22.48
  • Price/Book 17.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.66
  • Growth Rate Est. (year over year) +151,263.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.79 +6.79%
on 01/28/20
64.82 -1.50%
on 02/06/20
+2.71 (+4.43%)
since 01/21/20
3-Month
54.29 +17.61%
on 11/22/19
64.82 -1.50%
on 02/06/20
+9.81 (+18.15%)
since 11/21/19
52-Week
46.47 +37.40%
on 05/16/19
64.82 -1.50%
on 02/06/20
+14.19 (+28.57%)
since 02/21/19

Most Recent Stories

More News
Notice for the Annual General Meeting of Novo Nordisk A/S

Bagsvaerd, Denmark, 21 February 2020 - The Annual General Meeting of Novo Nordisk A/S will be held on:

NVO : 63.85 (+0.54%)
Companion Medical's InPen Diabetes Management System Receives FDA Clearance for use with Fiasp® Insulin

Companion Medical, manufacturer of InPen, the first FDA-cleared smart insulin pen and mobile app-based diabetes management system, today announced clearance by the FDA for the use of Novo Nordisk's Fiasp®...

NVO : 63.85 (+0.54%)
Global Insulin Drugs Industry Forecasts 2020-2030 - Novo Nordisk's 2020 Diabetes Pill Expected to Generate About $5 Billion in Annual Sales

The "Insulin Drugs Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering.

NVO : 63.85 (+0.54%)
Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split

Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.

SNY : 50.85 (+0.20%)
NVO : 63.85 (+0.54%)
ABBV : 94.96 (+0.77%)
MRK : 82.34 (-0.18%)
BMY : 65.63 (+0.71%)
GSK : 43.08 (+0.75%)
Global Insulin Drugs Markets, 2015-2019 & 2020-2030 - Key Players are Apidra, Eli Lilly, Humalog, Humulin, Insuman, Lantus, Levemir, Novo Nordisk, Novomix, and NovoRapid/Novolog

The "Insulin Drugs Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering.

LLY : 142.04 (+0.03%)
NVO : 63.85 (+0.54%)
Global Diabetes Devices Market Analysis 2016-2026: Covering Sinocare, Sanofi & Novo Nordisk Among Others - ResearchAndMarkets.com

The "Global Diabetes Devices Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

NVO : 63.85 (+0.54%)
Novo Nordisk (NVO) Q4 Earnings Match Estimates, Revenues Beat

Novo Nordisk (NVO) posts in-line earnings, while revenues beat estimates in the fourth quarter of 2019.

PFE : 35.72 (-0.36%)
NVO : 63.85 (+0.54%)
RHHBY : 44.0300 (+0.39%)
SNY : 50.85 (+0.20%)
Novo Nordisk: 4Q Earnings Snapshot

BAGSVAERD, Denmark (AP) _ Novo Nordisk A/S (NVO) on Wednesday reported fourth-quarter profit of $1.29 billion.

NVO : 63.85 (+0.54%)
Novo Nordisk's operating profit increased by 11% in Danish kroner and by 6% at constant exchange rates (CER) in 2019

Financial report for the period 1 January 2019 to 31 December 2019

NVO : 63.85 (+0.54%)
Rybelsus(R) (oral semaglutide) recommended for approval for the treatment of adults with type 2 diabetes by the European regulatory authorities

Bagsvaerd, Denmark, 31 January 2020 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion,...

NVO : 63.85 (+0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade NVO with:

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

2nd Resistance Point 64.34
1st Resistance Point 64.09
Last Price 63.85
1st Support Level 63.56
2nd Support Level 63.28

See More

52-Week High 64.82
Last Price 63.85
Fibonacci 61.8% 57.81
Fibonacci 50% 55.65
Fibonacci 38.2% 53.48
52-Week Low 46.47

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar